Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?

URN to cite this document:: urn:nbn:de:bvb:355-epub-431773
DOI to cite this document:: 10.5283/epub.43177

Bredthauer, Andre

; Kopfmueller, Manuel ; Gruber, Michael

; Pfaehler, Sophie-Marie ; Lehle, Karla ; Petermichl, Walter ; Seyfried, Timo ; Bitzinger, Diane I. ; Redel, Andreas

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(676kB)

Date of publication of this fulltext: 12 May 2020 11:52

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Introduction. Anticoagulants such as argatroban and heparins (low-molecular-weight and unfractionated) play an immense role in preventing thromboembolic complications in clinical practice. Nevertheless, they can also have a negative effect on the immune system. This study is aimed at investigating the influence of these substances on polymorphonuclear neutrophils (PMNs), whose nonspecific defense ...